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A B S T R A C T
Background: B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in the Western world. Major progress has been made in assessing typical chromosomal abnormalities and recognition of the correlation of these chromosomal abnormalities with laboratory features and clinical course of the disease. The most frequent genomic changes are deletions at 13q14, 11q22-23 and 17p13 and trisomy of chromosome 12.
Objectives: The aim of this study was to investigate the frequency of chromosomal aberrations in B-CLL patients’ peripheral blood and/or bone marrow using a molecular cytogenetic method, interphase fluorescence in situ hybridization (I-FISH) and to evaluate the correlation between these genomic changes and clinical findings.
Patients and Methods: I-FISH analyses were performed on bone marrow and blood samples of 66 B-CLL patients.
Results: Deletion of 17p13 was found in 11 (16.6%) and deletion 6q21 was present in 5 (7.5%). Statistical analyses were performed to investigate the correlation of these molecular-cytogenetic findings with family history, Rai staging and CD38 marker. No clear differences in distribution was noted for del17p13 and del6q21 among patients with and without family history, and no direct correlation was noted between these genomic changes and CD38 marker, but the correlation of del17p13 and Rai stage was significant. There was a high frequency of Rai stage II within del17p13 patients.
Conclusions: It was demonstrated that the presence of del6q21 in B-CLL patients indicates poor prognosis and on the contrary, presence of del17p13 points at the good prognostic value of the disease.
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Implication for health policy/practice/research/medical education:FISH analysis in B-CLL patients is improving diagnosis and helps to manage the disease better. Considering the high frequency of del17p13 observed within patients in this study, we recommend that cytogenetic evaluation of del17p13 be performed for patients routinely.
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1. BackgroundB-cell chronic lymphocytic leukemia (B-CLL) is usually described as the most common leukemia in the United States, Canada, and Western Europe, whereas it is rare in Japan and infrequent in other Asian societies (1). CLL is with an incidence of 30% among the entire leukemia’s 
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nophenotype (CD5, CD19, CD20, and CD23 positive) (5-7). Clinical course of the disease is highly variable. Some patients show symptoms at diagnosis or early thereaf-ter and need early therapy, but others have no or mini-mal symptoms for many years (8). Infrequently, there are constitutional symptoms; on the contrary, the most frequent physical finding is lymphadenopathy, which is followed by splenomegaly. Other symptoms are fatigue, infection and autoimmune hemolytic anemia. There are several treatments for B-CLL patients such as using mono-clonal antibodies, new experimental drugs and stem cell transplantation (autologous or allogeneic) (9). Variable prognosis is carried by B-CLL, which is associated with distinct parameters such as genetic aberrations that are helpful to predict the clinical outcome of the disease (10, 11). Age, sex, and clinical staging (Rai or Binet staging), pe-ripheral blood lymphocyte count, lymphocyte-doubling time, bone marrow (BM) histology, serum thymidine kinase, and serum β2-microglobulin levels have all been identified as important independent prognostic factors (12-15). Chromosomal aberrations in B-CLL rose to more than 80% (16-18), which means that genetic markers could have a critical role in prediction and diagnosis of B-CLL. The most frequent aberrations are: 1) Deletion on the long arm of chromosome 13 (13q14) in > 50% of the cases (19); 2) Trisomy of chromosome 12 in 10–20% of the cases; 3) Deletions in bands 11q22–q23 in 10–20% of the cases, where the ATM gene is located (20-22); 4) Deletion on the short arm of the chromosome 17 (17p13). Association of Deletion 11q22 and 17p13 with poor prognosis and dele-tion 13q14 with good prognosis has been demonstrated (23). Trisomy 12 is correlated with atypical morphology and shortened survival (worse prognosis) (24, 25). Con-ventional cytogenetic methods can detect 40-50% abnor-malities in B-CLL patients (26, 27), while using fluorescent in situ hybridization (FISH) has brought the sensitivity of cytogenetic analysis to a higher level, by which, 80% of abnormalities can be detected (28). In the previous study, we analyzed the correlation of del (13q), del (11q) and tri-somy 12 with features of B-CLL in Iranian cases (29).
2. ObjectivesThe aims of this study were first to verify the frequency of del (6q21) and del (17p13) in B-CLL patients by conven-tional cytogenetic methods and FISH technique, and second to determine the correlation between these two abnormalities and prognostic factors, including Rai stag-ing, CD38 marker and family history.
3. Patients and MethodsPatients were recruited for 20 months between 2008 and 2010 from four major hematology/oncology hos-pitals in Tehran, Iran. The patients were new cases or al-ready identified as B-CLL cases and not taking any thera-peutic treatment for six months before sampling. The 
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4. ResultsThe culture of four cases failed, and 66 specimens were successfully analyzed. In Table 1, patients’ clinical charac-teristics are summarized. The gender ratio was 2.9 with 49 male and 17 female patients. Patients were 40 to 81 years old with the mean age of 61.73 years old. They could be classified into two subgroups. Twenty three cases have 
been recently diagnosed (new cases), and they were fol-lowing their clinical diagnosis. Forty three cases suffered from the disease from 8 to 236 months. The number of bone marrow specimens in Table 1 is actually the sum of cases with bone marrow and cases with both bone mar-row and peripheral blood samples. The information of Rai staging and family history is also available in Table 1.
Table 1. Clinical and Laboratory Features of Iranian B-Cell Patients
Patients Genomic Changes Total (n = 66)
Del 6q21 (n = 4) Del 17p13 (n = 11)
Gender, No.Male 1 10 49Female 3 1 17
Age, y, No.< 50 0 1 850-60 0 4 1760-70 2 4 25> 70 2 2 16
TissueBMa 2 6 27PBa 3 6 32
Rai stageO 0 0 6I 0 1 9II 3 3 31III 1 6 15IV 0 1 5
Family 
historyPositive 1 9 15Negative 3 2 47a Abbreviation: BM, bone marrow; PB, peripheral blood
Interphase FISH for del (6q21) and del (17p13) was per-formed on 66 patients; out of which 5 cases demonstrat-ed the micro deletion in 6q21 (5/66 or 7.5%); and 11 cases turned out to have the micro deletion in 17p13 (11/66 or 16.6%); among these 16 patients with these chromosomal abnormalities, one patient had both del (6q21) and del (17p13). The range of abnormalities was different in pa-tient’s specimens. Compared to cut off points for positive values, this range verified the abnormalities in patients properly. Correlation of family history and del (17p13) were analyzed by Chi square (P = 0.48 for Fisher’s exact test) and did not show any significance. This test also was performed between family history and del (6q21) (P = 1.000 for Fisher’s exact test) but the correlation was not significant. The Mann-Whitney test was considered for analyzing the correlation between Rai staging and del (6q21). The result was P = 0.7, which means there is no 
significance. This test was repeated for the correlation of chromosomal abnormalities and CD38. The result for del (6q21) and del (17p13) was P = 0.368 and P = 0.13 respec-tively, which means CD38 did not have significance in any of these two abnormalities. FISH analysis revealed 22.7% chromosomal abnormalities in total comprising 7.5% for del (6q21) and 16.6% for del (17p13). The results of other published studies and the current study are summarized in Table 2.
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males because, some female patients avoided to take part in the study. There were two reasons why bone marrow specimens were less than peripheral blood samples. First, the greater numbers of cases were those who had already been diagnosed as B-CLL and the physicians did not feel necessary to perform another bone marrow aspiration; second, an analysis of both bone marrow and blood sam-ples demonstrated that there are no differences between these two tissues in FISH results and patients prefer to give blood samples instead of bone marrow aspiration. So the number of peripheral blood specimens increased 
in this study. The weak mitogen stimulation of malignant cells in B-CLL and the fact that in B-CLL unlike other forms of leukemia, the cells are in G0 phase of the cell cycle, we had a decrease of metaphases in the cytogenetic analy-sis. Moreover, many of the chromosomes were small and short and less liable to good banding. So it was so difficult to identify chromosomal abnormalities such as translo-cations, inversions and micro deletions. Because of these reasons, we could just identify 27.7% chromosomal abnor-malities using conventional cytogenetic methods. 
Table 2. Detection Rate of Cytogenetic Aberrations byFIsh Analysis in Different Populations
No Reference Country Del 17p13, % Del 6q21, % FISH Abnormality, No. (%)
1 Gunn et al. (32) USA 4.6 7.5 174 (89)
2 Gaidano et al. (33) USA 4 10 100 (14)
3 Dohner et al. (34) Germany 12 - 90 (12)
4 Dohner et al. (17) Germany 7 6 325(82)
5 Chevallier et al. (35) France 7 - 111 (75)
6 Haferlach et al. (36) Germany 7 4.6 500 (78.4)
7 Juliusson et al. (37) Sweden 4 6 649 (48)
8 Turgut et al. (38) Turkey 14 - 36 (47)
9 Sindelarova et al. (39) Czech republic 16 - 206 (16)
10 Durak et al. (40) Turkey 7.6 - 79 (50.6)
11 Dewald et al. (41) USA 8 0 113 (77)
1 Dicker et al. (42)                      USA                                    5.3                                                7                               132 (79)
1 Present study                            Iran                                    16.6                                             7.5                                              66 (22.7)
As mentioned before, up to 80% of chromosomal abnor-malities in B-CLL patients could be detected using I-FISH (43). Oscier et al. (44), using FISH; found chromosomal ab-errations in 69% of patients , Dewald et al. (41), found 77%; Chena et al. (2), 80.7%; Gunn et al. (32), 89%; and Dohner et al. (17), 82%. In some of these studies (17, 41), B-CLL pa-tients were examined for deletion of 13q, 11q, and 17p; also for 6q, 14q chromosomal abnormalities and for 8q24 and 3q trisomy (17). So the rate of chromosomal aberrations detected by FISH is high. The greater detection of chro-mosomal abnormalities by FISH method in comparison to conventional cytogenetic methods reveals the higher sensitivity of this method. Therefore, FISH testing helps outstandingly in establishing a diagnosis for these pa-tients. In our study where I-FISH was only used for two genomic changes and patients were examined with two DNA probes (for detection of deletion 6q21 and deletion 17p) we could identify these abnormalities in just 22.7% of patients, comprising 16.6% for del 17p13 and 7.5% for del 6q21. The results of this study and some similar studies are summarized in Table 2. We found deletion of TP53 gene on 17p13 in 11 (16.6%) of studied cases. In addition to dele-tion of 17p13 chromosomal band or occurring mutations in TP53 gene, inactivation of this gene could be because of other factors. For example Pettitt et al. (45) revealed that p53 inactivation occurred because of defects of ATM pro-







FISH Analysis in B-cell Chronic Lymphocytic Leukemia Teimori H et al.
111Iran Red Crescent Med J. 2013:15(2)




References1.       Faguet GB. Chronic Lymhocytic Leukemia: Molecular Genetics, Biolo-gy, Diagnosis, and Management. New Jersey: Humana Press; 2004. 2.       Chena Christian, Arrossagaray Guillermo, Scolnik Mariano, Pala-cios Marı́a F, Slavutsky Irma. Interphase cytogenetic analysis in Argentinean B-cell chronic lymphocytic leukemia patients: asso-ciation of trisomy 12 and del(13q14). Cancer genetics and cytogenet-ics.2003;146(2):154-160.3.       Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med.1995;333(16):1052-7.4.       Karimi M, Mehrabani D, Yarmohammadi H, Jahromi FS. The prevalence of signs and symptoms of child ood leukemia and lymphoma in Fars Province, Southern Iran. Cancer Detect Prev.2008;32(2):178-83.5.       Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leuke-mia: a bird of a different feather. J Clin Oncol.1999;17(1):399-408.6.       Dierlamm J, Michaux L, Criel A, Wlodarska I, Van den Berghe H, Hossfeld DK. Genetic abnormalities in chronic lymphocytic leu-kemia and their clinical and prognostic implications. Cancer Genet Cytogenet.1997;94(1):27-35.7.       Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmu-tated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood.1999;94(6):1848-54.8.       Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified ap-proach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol.2007;20(3):439-53.9.       Pangalis GA, Vassilakopoulos TP, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Angelopoulou MK. B-chronic lymphocytic leukemia: practical aspects. Hematol Oncol.2002;20(3):103-46.10.       Amiel A, Leopold L, Gronich N, Yukla M, Fejgin MD, Lishner M. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia. Can-cer Genet Cytogenet.2006;167(2):145-9.11.       Oscier D. Biology and prognostic factors in CLL. Hematolo-gy.2005;10 Suppl 1:197-9.12.       Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Can-







FISH Analysis in B-cell Chronic Lymphocytic LeukemiaTeimori H et al.
Iran Red Crescent Med J. 2013:15(2)112
hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn. 2008;10(5):442-51.33.       Gaidano G, Newcomb EW, Gong JZ, Tassi V, Neri A, Cortelez-zi A, et al. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Am J Pathol.1994;144(6):1312-9.34.       Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood.1995;85(6):1580-9.35.       Chevallier P, Penther D, Avet-Loiseau H, Robillard N, Ifrah N, Mahe B, et al. CD38 expression and secondary 17p deletion are impor-tant prognostic factors in chronic lymphocytic leukaemia. Br J Haematol.2002;116(1):142-50.36.       Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Com-prehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, inter-phase FISH, IgV(H) status and immunophenotyping. Leuke-mia.2007;21(12):2442-51.37.       Juliusson G, Oscier D, Gahrton G, Fitchett M, Ross FM, Brito-Baba-pulle V. Cytogenetic findings and survival in B-cell chronic lym-phocytic leukemia. Second IWCCLL compilation of data on 662 patients. Leukemia & Lymphoma.1991;5(S1):21-5.38.       Turgut B, Vural O, Pala FS, Pamuk GE, Tabakcioglu K, Demir M, et al. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma.2007;48(2):311-20.39.       Sindelarova L, Michalova K, Zemanova Z, Ransdorfova S, Brezino-va J, Pekova S, et al. Incidence of chromosomal anomalies detect-ed with FISH and their clinical correlations in B-chronic lympho-cytic leukemia. Cancer Genet Cytogenet.2005;160(1):27-34.40.       Durak B, Akay OM, Aslan V, Ozdemir M, Sahin F, Artan S, et al. Prognostic impact of chromosome alterations detected by FISH in Turkish patients with B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet.2009;188(2):65-9.41.       Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol.2003;121(2):287-95.42.       Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immuno-stimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood.2006;108(9):3152-60.43.       Stilgenbauer S, Lichter P, Dohner H. Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hema-tol.2000;4(1):48-72.
44.       Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mu-tation of the p53 gene are independent prognostic factors. Blood.2002;100(4):1177-84.45.       Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leu-kemia: inactivation of ATM as an alternative to TP53 mutation. Blood.2001;98(3):814-22.46.       Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chro-mosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med (Berl).1999;77(2):266-81.47.       Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leuke-mia.2002;16(6):993-1007.48.       Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ, et al. Prognostic subgroups in B-cell chronic lymphocytic leu-kemia defined by specific chromosomal abnormalities. N Engl J Med.1990;323(11):720-4.49.       Offit K, Louie DC, Parsa NZ, Filippa D, Gangi M, Siebert R, et al. Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). Blood.1994;83(9):2611-8.50.       Stilgenbauer S, Bullinger L, Benner A, Wildenberger K, Bentz M, Dohner K, et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leuke-mia.1999;13(9):1331-4.51.       Jackson A, Panayiotidis P, Foroni L. The human homologue of the Drosophila tailless gene (TLX): characterization and mapping to a region of common deletion in human lymphoid leukemia on chromosome 6q21. Genomics.1998;50(1):34-43.52.       Sherratt T, Morelli C, Boyle JM, Harrison CJ. Analysis of chromo-some 6 deletions in lymphoid malignancies provides evidence for a region of minimal deletion within a 2-megabase segment of 6q21. Chromosome Res.1997;5(2):118-24.53.       Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert R, Fitch-ett M. Correlation of chromosome abnormalities with labora-tory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol.1990;76(3):352-8.54.       Aoun P, Zhou G, Chan WC, Page C, Neth K, Pickering D, et al. Famil-ial B-cell chronic lymphocytic leukemia: analysis of cytogenetic abnormalities, immunophenotypic profiles, and immunoglob-ulin heavy chain gene usage. Am J Clin Pathol.2007;127(1):31-8.55.       Ng D, Toure O, Wei MH, Arthur DC, Abbasi F, Fontaine L, et al. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood.2007;109(3):916-25.
